Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute
Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute
This study is designed to perform a head-to-head comparison of two synthetic ceramic bone
 graft substitutes, bioactive glass (BAG) and beta-tricalcium phosphate (TCP), in filling of
 contained bone defects following surgical evacuation of benign bone tumor or tumor-like
 conditions. Based on the investigators' previous preclinical research and an ongoing
 single-center randomized clinical trial on bioactive glass filling, the investigators expect
 BAG filling to be more efficient compared to TCP in promotion of defect healing and
 functional recovery after surgery.
This study is designed to perform a head-to-head comparison of two synthetic ceramic bone
 graft substitutes, bioactive glass (BAG) and beta-tricalcium phosphate (TCP), in filling of
 contained bone defects following surgical evacuation of benign bone tumor or tumor-like
 conditions. Small metacarpal and phalangeal enchondromas (Stratum I) and large long-bone
 lesions (Stratum II) will be evaluated separately. Aside with the head-to-head comparison of
 the two synthetic bone graft substitutes, autologous bone graft (Stratum I) and allogeneic
 bone graft (Stratum II) will be used as the standard of care controls.
Inclusion Criteria:

 -  Patients with primary or recurrent benign bone tumor or tumor-like condition that
 requires operative treatment by means of tumor evacuation and defect filling

 -  Pathological fractures of patients in Stratum I are treated by means of conservative
 treatment for three months before tumor surgery

 Exclusion Criteria:

 -  History of acute or chronic local infection

 -  History of malignancy (excluding carcinoma basocellular) within past 5 years

 -  A history of local radiotherapy

 -  A known metabolic skeletal disease (such as osteoporosis, Paget's disease or
 osteomalacia)

 -  Medication affecting bone turnover (oral bisphosphonates, PTH, sodium fluoride,
 strontium ranelate, calcitonin, testosterone, systemic cortico- or anabolic steroids)

 -  Any plans to use phenol or other chemical/thermal method of local tumor control

 -  Pregnancy

 -  Any other condition that in the judgment of the investigator, would prohibit the
 subject from participating in the study or may hinder the collection of data and
 interpretation of the results